Amedisys (AMED) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Supermicro raises Q1 FY2027 revenue outlook on AI demand
- Dow outperforms as Wall Street rises, healthcare stocks lead gains
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
Amedisys Reports Second Quarter 2021 Financial Results, Closing of Contessa Acquisition, Expansion of Credit Facility and Authorization of New $100 Million Share Repurchase Program
August 4, 2021 4:05 PM EDTBATON ROUGE, La., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2021.
Three-Month Periods Ended June 30, 2021 and 2020
Net service revenue increased $79.2Â million to $564.2Â million compared to $485.0Â million in 2020.Net income attributable to Amedisys, Inc. of $80.1Â million compared to $34.7Â million in 2020.Net income attributable to Amedisys, Inc. per diluted share of $2.43 compared to $1.04 in 2020.Adjusted Quarterly Results*
Adjusted EBITDA of $83.8Â million compared to $66.4Â million in 2020.Adjusted net service revenue of $557.6Â million compared to $485.0Â million in... More


